See what questions
a doctor would ask.
Amgen Inc. has informed health-care professionals about the risk of cardiovascular problems such as blood clots associated with the anemia drug, Aranesp, when it is taken in doses higher than the recommendation. The FDA requested the warning be delivered after trials on similar drugs produced cardiovascular side effects when taken in higher doses. The drug is aimed at dialysis or chemotherapy patients who develop anemia. Despite the warning, the company representatives claim that they did not observe these side effects during their own clinical trials.
Source: summary of medical news story as reported by AJC - HealthDay
About: Warnings highlight possible risk associated with anemia drug
Date: 15 January 2005
Source: AJC - HealthDay
http:/ This summary article refers to the following medical categories:
Related Medical Topics
More News Topics
This summary article refers to the following medical categories:
Search Specialists by State and City